Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML 2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML 2026-03-08T22:24:18-07:00August 16th, 2022|2022 Press Releases, Press Releases| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine 2025-08-26T08:08:16-07:00May 9th, 2022|2022 Press Releases, Press Releases| Read more